TITLE

Enoxaparin was more effective than unfractionated heparin in STEMI, regardless of type of fibrinolytic agent used

PUB. DATE
November 2007
SOURCE
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p63
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on a study that investigates the effectiveness of enoxaparin, in comparison with unfractionated heparin (UFH), for patients with ST-elevation myocardial infarction (STEMI), irrespective of the type of fibrinolytic agent used. It describes the method and patients' condition for the study. The study revealed that patients with STEMI, enoxaparin reduced risk for nonfatal myocardial infarction, but increased risk for major bleeding.
ACCESSION #
28019865

 

Related Articles

  • Myocardial infarction: the first 24 hours. Lipkin, David P.; Reid, Colin J. // British Medical Journal (Clinical Research Edition);4/2/1988, Vol. 296 Issue 6627, p947 

    Discusses guidelines on the management of myocardial infarction in the Great Britain. Effects of the early use of thrombolytic treatment on patients with acute myocardial infarction; Information on coronary artery occlusion and coronary vasoconstriction; Details on prophylactic lignocaine.

  • Can BRIGHT Restore the Glow of Bivalirudin? Cavender, Matthew A.; Faxon, David P. // JAMA: Journal of the American Medical Association;4/7/2015, Vol. 313 Issue 13, p1323 

    The authors focus on the results of the Bivalirudin in Acute Myocardial Infarction Versus Heparin and Glycoprotein IIb/IIIa Inhibitors (GPI) Plus Heparin Trial (BRIGHT) conducted by Y. Han and colleagues. The trial studies direct thrombin inhibitor bivalirudin in patients undergoing percutaneous...

  • Pharmacological effects and clinical applications of ultra low molecular weight heparins. Zhang Liu; Shengli Ji; Juzheng Sheng; Fengshan Wang // Drug Discoveries & Therapeutics;Feb2014, Vol. 8 Issue 1, p1 

    Heparin, one of the common anticoagulants, is clinically used to prevent and treat venous thromboembolism (VTE). Though it has been the drug of choice for many advanced medical and surgical procedures with a long history, the adverse events, such as bleeding, heparin-induced thrombocytopenia...

  • Antithrombotic drugs increase risk of bleeding in myocardial infarction patients.  // Australian Journal of Pharmacy;Apr2010, Vol. 91 Issue 1079, p94 

    The article presents a study on the association of antithrombotic drugs to bleeding in patients with myocardial infarction. Study shows that the drugs increase of bleeding in the patients. It notes that the risk of hospital admission among these patients increased with those with those using...

  • Heparin for acute MI is not necessarily the best course.  // Modern Medicine;Jul98, Vol. 66 Issue 7, p29 

    Presents an abstract of the article `Use and Effectiveness of Intravenous Heparin Therapy for Treatment of Acute Myocardial Infarction in the Elderly,' by H. M. Krumholz, J. Hennen, et al from the `Journal of American College Cardiol' dated April 1998.

  • Tenecteplase. Tsikouris, James P.; White, C. Michael // Formulary;Aug2000, Vol. 35 Issue 8, p647 

    Focuses on tenecteplase, a novel fibrin-specific thrombolytic agent approved for the reduction of mortality associated with acute myocardial infarction (AMI). Association with a lower incidence of noncerebral bleeding; Decreased need for blood transfusions compared with alteplase (rt-PA);...

  • Reteplase for Acute Myocardial Infarction.  // American Family Physician;3/1/1997, Vol. 55 Issue 4, p1464 

    Reveals that the United States' Food and Drug Administration has approved the thrombolytic agent reteplase for use in the management of acute myocardial infraction in adults. Information on reteplase; Details on studies conducted on the effect of the drug; Number of patients who participated in...

  • Thrombolytic agent for MI.  // Geriatrics;Feb97, Vol. 52 Issue 2, p28 

    Features reteplase (Retavase), an intravenous thrombolytic agent for the management of acute myocardial infarction. Improvements for ventricular function; Reduction of the incidence of MI-associated congestive heart failure and mortality; Contraindication.

  • Prairie paramedics test new weapon against MIs. Basky, Greg // CMAJ: Canadian Medical Association Journal;11/28/2000, Vol. 163 Issue 11, p1490 

    Focuses on plans to test the effectiveness of the thrombocytic drug tenecteplase as of November, 2000. How paramedics in Saskatchewan and Alberta, Canada will use the drug on heart attack patients in the field as part of a clinical trial; Statement that studies have shown tenecteplase to be as...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics